(1)

Thomas Anthony Dooley III was born in St. Louis in 1927, the second son of an Irish-Catholic family. From the beginning, he possessed the combination of qualities: an inexhaustible appetite for work, a performing instinct that could fill a room, and a conviction that he was meant to make a difference. He enlisted in the Navy at seventeen, trained as a hospital corpsman, and after the war earned his medical degree from St. Louis University in 1953.

 In 1954, assigned to Operation Passage to Freedom, he spent months treating nearly a million North Vietnamese refugees fleeing south after the fall of Dien Bien Phu, working sixteen-hour days on transport ships in the South China Sea, handling dysentery, tuberculosis, and trauma at a scale medical school had not prepared him for. He was always a man of action. Even after discharged by the Navy, he entered Laos to build a network of jungle hospitals, wrote three bestselling books, and founded the Medical International Cooperation Organization (MEDICO), which by his death was running seventeen projects across twelve nations. In the equatorial tropics, his fair Irish skin absorbing the accumulated radiation of the sun without a thought. There were patients coming to see him.

In 1959, back in the United States on a fundraising circuit, Dooley found a lump near his shoulder. Biopsy and diagnosis confirmed that it was malignant melanoma, arising from the sun-damaged skin of his upper chest — the site and subtype one would predict in a fair-skinned man with years of unprotected tropical UV exposure. He was thirty-two.

To rouse the public's awareness of melanoma, he agreed to let CBS News film his surgery at Memorial Sloan Kettering. The cameras filmed the three-hour operation, his recovery, and an interview in which he spoke plainly about what he knew. On April 21, 1960, Biography of a Cancer was broadcast nationally, hosted by Howard K. Smith. On television, Dooley's doctor told him he would survive for years. He told the cameras: Walt Whitman said it's not important what you do with the years of your life, but how you use each hour. That's how I want to live. 

For metastatic melanoma in 1959, medicine had nothing to offer. No chemotherapy, no immunotherapy, no targeted drug. Dacarbazine (DTIC), the first agent that would eventually be approved for the disease, was sixteen years from existence, and when it finally arrived it would help barely fifteen percent of patients with no survival benefit. The physicians at the finest cancer institution in America could excise the primary tumor and then stand with their hands open.

Dooley returned to his hospitals in Laos anyway. By the summer of 1960, the melanoma had reached his lungs, liver, spleen, heart, and brain; the systemic colonization that is the disease's particular cruelty. By December, his spine had failed; physicians in Hong Kong fitted him with a steel and leather harness from shoulders to hips to hold him upright. He still saw patients and wrote letters. 

In January 1961 he flew back to New York. There was no protocol left, no last resort. On his thirty-fourth birthday, Cardinal Spellman visited and a telegram arrived from President Eisenhower praising his service to distant peoples. He died the following evening, January 18, 1961.
The eulogies spoke of the hospitals, the books, the refugees, and the Peace Corps Kennedy would found citing his example. What not being said was that Dooley had died because of the long, flat, hopeless plateau of melanoma treatment that would not break for another fifty years.

The oncologists who attended him were not negligent or uninformed. They were the best the country had, working at its finest cancer institution. Surgery could remove a primary tumor on the skin with a clear margin. Radiation could shrink a mass pressing on the organs to buy a few weeks of less pain. Beyond that, there was nothing. No drug had been approved for melanoma. Researchers tried nitrogen mustard, actinomycin, or combinations that made patients sick without making tumors smaller. The disease ignored all of it.

The numbers told the story with frustration for the time. Five-year survival for patients with distant metastatic melanoma hovered near five percent throughout the 1960s, the 1970s, and the 1980s, a figure so grim it was almost indistinguishable from zero. Median survival after a diagnosis of Stage IV disease was measured not in years but in months: six to nine, typically. That condition — competent physicians, excellent institutions, and nothing that worked — would persist essentially unchanged for the next four decades. Fourteen years after Dooley's death,   dacarbazine (DTIC) was approved in 1975, which helped one patient in seven and cured none. Through the brutal biochemotherapy regimens of the 1980s and the failed vaccine trials of the 1990s, the survival curve for metastatic melanoma barely moved. The incidence, meanwhile, was rising steadily at roughly three to five percent annually. More patients arriving in the absence of effective treatment.

(2)

During those years of stagnation, doctors tried very hard to move the field forward inch by inch. Wallace Clark Jr. had built the field of melanoma pathology almost single-handedly. Before Clark, melanoma was described in the language of appearance: dark, irregular, spreading, dangerous. Pathologists could confirm that a lesion was malignant. What they could not do was telling a surgeon or an oncologist how dangerous this particular melanoma was likely to be, or how far it had already gone. Clark changed this by looking at where the tumor cells were in relation to the anatomical layers of the skin, and he turned that relationship into a classification system.

Working at Massachusetts General Hospital and later at the University of Pennsylvania, Clark and his colleagues described five levels of melanoma invasion in a landmark 1966 paper that would become one of the most cited in the history of dermatologic oncology. The levels were anatomical. Level I meant the tumor was confined to the epidermis — the outermost layer — and had not penetrated below it. Level II described invasion into the uppermost part of the dermis, the papillary dermis, where the tumor cells had crossed the basement membrane but not yet expanded to fill it. Level III meant the tumor had grown to fill and expand the papillary dermis, pressing against but not yet entering the deeper reticular dermis. Level IV marked invasion into the reticular dermis itself. Level V described penetration through the dermis entirely, into the subcutaneous fat below. The deeper the level, Clark and his colleagues found, the worse the prognosis. A Level I melanoma was almost universally curable with surgery. A Level V melanoma carried a survival rate that the actuarial tables recorded in flat numbers that concealed the human devastation behind them.

Clark's levels gave the field a shared language where before there had been only individual impression. For the first time, pathologists reading a melanoma slide could produce a number — a level — that carried standardized, communicable prognostic weight. Surgeons could plan their margins with more information. Oncologists could speak to patients about risk in terms that meant something reproducible. Tumor boards could compare cases across institutions. 

It was not a perfect system. Reproducibility between pathologists — particularly for the borderline Levels II and III — was not always high. But it was Clark who had first imposed order on the chaos, who had looked at an undifferentiated category called melanoma and shown that within it there was a spectrum — a series of defined stages with different biological meanings and different human consequences. That act of classification was not merely academic. For patients, it meant the difference between leaving a biopsy appointment with a number that indicated cure and leaving with a number that indicated the need for radical intervention. For the first time, the slide told a story the patient could be told.

Having given melanoma a vertical grammar — depth of invasion — Clark turned his attention in the mid-1970s to a question that unsettled him in a different way: the families with too many moles.

He had seen them in his practice, patients with dozens of large, irregular, discolored nevi scattered across their backs and shoulders and scalps — not quite normal moles and not quite melanomas, but something in between that his training had not given him a precise category for. What troubled him more than the nevi themselves was the pattern they traveled with: in certain families, melanoma struck generation after generation, appearing in siblings and parents and aunts at rates that no random distribution could explain.

Clark, working with colleagues including David Elder and others at Penn, began systematically documenting these families. The lesions he was seeing , were large, flat, with irregular borders and variable pigmentation, which were biologically distinct from common acquired nevi. Under the microscope, they showed architectural disorder and cytologic atypia that fell short of frank malignancy but exceeded anything that could be called normal. They were, Clark concluded, a distinct clinical entity: precursor lesions, or at the very least markers of dramatically elevated melanoma risk, clustered in families with a hereditary predisposition to the disease.

In 1978, he published the paper describing what he called the B-K mole syndrome  (the initials taken from two index families he had followed), characterizing for the first time the hereditary condition in which affected individuals carried a n unusual high, lifetime melanoma risk. The syndrome would migrate through nomenclature over the following two decades — dysplastic nevus syndrome, familial atypical multiple mole melanoma syndrome, the FAMMM syndrome — accumulating clinical refinement with each renaming.

What Clark had given the field was the concept of the high-risk individual who could be identified before the melanoma appeared. If the phenotypes (the profusion of large, atypical, variably pigmented nevi on someone with a strong family history) are recognizable, the high-risk population could receive periodical examination to detect change, remove anything that crossed from atypical into alarming, and counsel their siblings and children to do the same. It was the beginning of melanoma surveillance as a systematic clinical practice. Even without  treatment or cure, intervention upstream of the catastrophe can save people's lives.

And in the early 1970s in Nashville, Tennessee, a younger surgical pathologist named Alexander Breslow was doing something that his colleagues considered either inspired or obsessive: measuring melanomas with an ocular micrometer mounted to his microscope. He would demonstrate that raw tumor thickness, measured in millimeters with an ocular micrometer, carried even stronger prognostic power for most tumors than anatomical level. The two systems were eventually used together, each supplying what the other could not: Breslow thickness for primary prognostic power, Clark level for cases where thickness alone was ambiguous. Both names entered the staging criteria that governed melanoma management for decades.

By the early 1980s, Breslow thickness and Clark's level were being used together, the two measurements forming a scaffold on which the first rational staging system for melanoma would eventually be built. A thin melanoma, less than 0.76 millimeters, carried a five-year survival rate near ninety percent. A thick one, over four millimeters, carried a survival rate that the literature reported in flat, numeric terms that concealed the human wreckage behind them.
Pathology had given the disease a grammar. Surgery had given it a standard response. What neither could provide was an answer for the patient whose disease had already left the skin.

(3)
Diana Christine Merriweather was born in 1963. If you had met her, you would have noticed first the long curly red hair and the deep blue eyes, and then, the close-lipped smile with a slight tilt of the head. She had a natural grace and an unusual wit, a gift for humor and for practical jokes, and a love of small creatures that her husband Jeff — a Navy pilot on his way to becoming a NASA shuttle astronaut — found quietly endearing. 

One day she noticed that the mole on her back changed. The dermatologist excised it, sent it to the lab, and when the the pathological report came back with the notation of melanoma, assured her that the removal was the end of the matter. The margins were clear. She was cured except that it was not. What followed was what thousands of melanoma patients experienced in the 1980s and 1990s: the roller coaster of good news and bad, the sequence of doctor visits and surgeries that accumulated without producing resolution, the peculiar cruelty of a disease that retreated just far enough to seem beaten and then returned. Diana's melanoma came back. Then it came back again. By the summer of 1995, it had recurred a third time.

In 1995, there was little hope for metastatic melanoma patients, with only experimental trials and surgeries as treatment options. The FDA had approved dacarbazine in 1975, which helped roughly one patient in seven and cured none. High-dose interleukin-2, adjuvant Interferon therapy, and cancer vaccine were in trials, with unclear benefit but ensured side effects. Diana investigated all of it. She was not a scientist, yet she brought to her investigation the same quality of attention she brought to everything else. She read the literature, called oncologists, asked questions that the physicians around her found unusually precise for someone without medical training. What she found was disappointing: the treatments were not really working, the research was underfunded, and the gap no one currently had the tools to close.

The internet was just beginning in 1995, and chat rooms were starting to be used for sharing information, including some for melanoma patients. Diana latched onto these to find more information and would sometimes stay up well into the night, typing in the dark while Jeff slept, talking to other patients and the family members of patients. Diana was known for having an especially strong sense of compassion for fellow melanoma patients. As the disease spread to her organs and eventually to her brain, she kept searching relentlessly for something she could do for her chat room friends. Her frustration turned to determination after the tragic loss of several friends to melanoma and the third recurrence of her own tumors. She started making plans and then phone calls.

In 1996, Diana Merriweather Ashby founded the Melanoma Research Foundation (MRF). Its stated purposes were three: to support medical research toward effective treatments and eventually a cure; to educate patients and physicians about prevention, diagnosis, and treatment; and to advocate for the melanoma community to raise awareness of the disease and the need for a cure. She worked night and day, finally stopping only when the cancer had taken her eyesight and her voice.

She died on May 2, 1997, at the age of thirty-four years old. The Melanoma Research Foundation was eight months old. Jeff Ashby, in the years after her death, flew his first space shuttle mission and dedicated it to Diana and to the cause of melanoma awareness. When he spoke about her, he came back to the same image: a woman who had been inspired by her own journey and the absence of treatments available to her, and who had turned entirely toward others. It was pretty remarkable, he said, in the understated way of people who have seen something they cannot fully account for.

What the MRF became after Diana's death — the grants funded, the congressional appropriations secured, the researchers convened, the patients guided through a disease that no longer killed quite as efficiently as it once had — none of that was hers to see. But the patients who arrived at oncology clinics in the years that followed, the ones whose oncologists could offer something beyond surgery and DTIC and hope, answering to what she had asked in those late-night chat rooms: Is anyone doing something about this? Can something be done?

She had decided the answer was, yes.